Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
Line 5: | Line 5: | ||
! rowspan="5" |Category | ! rowspan="5" |Category | ||
! colspan="2" rowspan="5" |Condition | ! colspan="2" rowspan="5" |Condition | ||
! | ! rowspan="5" |Mechanism | ||
! colspan=" | ! colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para−clinical findings | |||
! colspan=" | |||
! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ! colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | |||
! colspan=" | |||
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs | ||
|- | |- | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | |||
! colspan=" | |||
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Severity | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |BP | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |PBS | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulopathy | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Coagulopathy | ||
|- | |- | ||
|- | |- | ||
! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infectious diseases | ! rowspan="16" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infectious diseases | ||
Line 54: | Line 35: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 85: | Line 58: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 106: | Line 71: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 126: | Line 83: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 157: | Line 106: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | | align="center" style="background:#F5F5F5;" + |Diagnosis of exclusion | ||
Line 174: | Line 115: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 195: | Line 128: | ||
!Bernard-Soulier syndrome | !Bernard-Soulier syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 204: | Line 134: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 218: | Line 143: | ||
!Gray platelet syndrome | !Gray platelet syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 227: | Line 149: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 246: | Line 163: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 264: | Line 173: | ||
!Thrombocytopenia with absent radius (TAR) syndrome | !Thrombocytopenia with absent radius (TAR) syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 273: | Line 179: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 287: | Line 188: | ||
!Alport syndrome | !Alport syndrome | ||
| | | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 296: | Line 194: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 312: | Line 205: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 336: | Line 221: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 360: | Line 237: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 384: | Line 253: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 408: | Line 269: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 438: | Line 291: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 460: | Line 305: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 484: | Line 321: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 507: | Line 336: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 530: | Line 351: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 554: | Line 367: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 577: | Line 382: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 612: | Line 409: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 636: | Line 425: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 660: | Line 441: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 684: | Line 457: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 708: | Line 473: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 732: | Line 489: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 757: | Line 506: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 782: | Line 523: | ||
| align="center" style="background:#F5F5F5;" + |Mild | | align="center" style="background:#F5F5F5;" + |Mild | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 807: | Line 540: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 831: | Line 556: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 855: | Line 572: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 876: | Line 585: | ||
! rowspan="4" |'''Bone marrow disorders''' | ! rowspan="4" |'''Bone marrow disorders''' | ||
!Myelodysplastic syndromes | !Myelodysplastic syndromes | ||
! | ! | ||
! | ! | ||
Line 900: | Line 601: | ||
|- | |- | ||
!Aplastic anemia | !Aplastic anemia | ||
! | ! | ||
! | ! | ||
Line 924: | Line 617: | ||
|- | |- | ||
!Acute leukemia | !Acute leukemia | ||
! | ! | ||
! | ! | ||
Line 948: | Line 633: | ||
|- | |- | ||
!Paroxysmal nocturnal hemoglobinuria (PNH) | !Paroxysmal nocturnal hemoglobinuria (PNH) | ||
! | ! | ||
! | ! | ||
Line 973: | Line 650: | ||
!'''Rheumatologic/autoimmune disorders''' | !'''Rheumatologic/autoimmune disorders''' | ||
!Systemic lupus erythematosus (SLE) | !Systemic lupus erythematosus (SLE) | ||
! | ! | ||
! | ! | ||
Line 1,000: | Line 669: | ||
! | ! | ||
!autoantibody-mediated syndrome | !autoantibody-mediated syndrome | ||
! | ! | ||
! | ! | ||
Line 1,025: | Line 686: | ||
! | ! | ||
!splenomegaly | !splenomegaly | ||
! | ! | ||
! | ! | ||
Line 1,050: | Line 703: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | ! | ||
Line 1,074: | Line 719: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | ! | ||
Line 1,098: | Line 735: | ||
! | ! | ||
!platelet destruction | !platelet destruction | ||
! | ! | ||
! | ! | ||
Line 1,123: | Line 752: | ||
! | ! | ||
!immune-mediated platelet destruction | !immune-mediated platelet destruction | ||
! | ! | ||
! | ! |
Revision as of 02:53, 13 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Mechanism | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | ||||||||||||||
Lab Findings | Imaging | ||||||||||||||
Severity | Fever | Bleeding | BP | Other | CBC | PBS | Coagulopathy | ||||||||
Infectious diseases | Gestational thrombocytopenia | ||||||||||||||
Chronic liver disease | |||||||||||||||
portal hypertension | |||||||||||||||
Hypersplenism | |||||||||||||||
Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | Diagnosis of exclusion | |||||||||||
Congenital platelet disorders | MYH-9 related disorders | ||||||||||||||
Bernard-Soulier syndrome | |||||||||||||||
Gray platelet syndrome | |||||||||||||||
Wiskott-Aldrich syndrome | |||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | |||||||||||||||
Alport syndrome | |||||||||||||||
Von Willebrand disease | |||||||||||||||
Infection | Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | |||||||||||||
HIV |
|
||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | |||||||||||||
Helicobacter pylori | Immune thrombocytopenia | ||||||||||||||
leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | |||||||||||||||
Intracellular parasites | Malaria | ||||||||||||||
Babesiosis | |||||||||||||||
Medications/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | ||||||||||||
Heparin-induced thrombocytopenia | |||||||||||||||
Cytotoxic chemotherapy | |||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | ||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||
Alcohol | |||||||||||||||
Malignancy | |||||||||||||||
Nutrient deficiencies | folate, vitamin B12, copper | an autoimmune mechanism | Mild | ||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | ||||||||||||||
Hemolytic uremic syndrome (HUS) | |||||||||||||||
Drug-induced TMA (DITMA) | |||||||||||||||
Bone marrow disorders | Myelodysplastic syndromes | ||||||||||||||
Aplastic anemia | |||||||||||||||
Acute leukemia | |||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||||
Rheumatologic/autoimmune disorders | Systemic lupus erythematosus (SLE) | ||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | ||||||||||||||
Felty's syndrome | splenomegaly | ||||||||||||||
vascular | giant capillary hemangioma, | platelet destruction | |||||||||||||
large aortic aneurysms, | platelet destruction | ||||||||||||||
cardiopulmonary bypass | platelet destruction | ||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction |